ERcast: Clinical Perspectives Podcast Preview

Subscription Required

Heme Potpourri: Superficial Thrombophlebitis, Iron Deficiency, and Estrogen

Tiffany Proffitt, DO and Tom Deloughery, MD

Sign in or Subscribe to listen.
5 starson Spotify
Sign in or Subscribe to view.Sign in or Subscribe to view.

The summary below is from an episode of ERcast: Clinical Perspectives

Estrogen is a consistent venous thromboembolism risk multiplier, increasing clot risk about threefold across pills, patches, and vaginal rings. Superficial thrombophlebitis is not always benign, and iron deficiency treatment often starts before the workup is complete when symptoms and follow-up make the diagnosis likely.

Estrogen and Clot Risk

  • Uniform VTE signal: All estrogen formulations and doses carry a similar venous thromboembolism signal, with an approximately threefold increase in clot risk rather than a meaningful low-dose or transdermal exemption.
  • Procoagulant mechanism: Estrogen shifts hemostasis toward thrombosis by lowering natural anticoagulants such as protein S and increasing procoagulants like factor VIII, plus likely direct vascular effects.
  • Gender-affirming hormone nuance: Estrogen in gender-affirming therapy also raises clot risk, while testosterone itself is not linked to VTE; hematocrit elevation is the lab red flag worth remembering.
  • ED relevance beyond OB-GYN: Hormone exposure matters in any chest pain, leg swelling, or PE workup because it changes pretest thinking more often than many emergency clinicians remember. We get into the practical framing in the episode.

Superficial Thrombophlebitis Management

  • Inflammatory clot biology: Superficial thrombophlebitis is usually an inflammatory venous process triggered by trauma or compression, not just a nuisance vein finding, which explains why symptoms can outpace appearance.
  • Low-risk local treatment: A small, distal, mildly symptomatic clot is usually managed conservatively with warm compresses and NSAIDs rather than full anticoagulation.
  • High-risk extension pattern: Clots larger than 5 cm or near the proximal greater saphenous vein carry meaningful DVT extension risk and deserve prophylactic-intensity anticoagulation rather than reassurance alone.
  • LMWH first-line choice: Enoxaparin 40 mg subcutaneously daily is the preferred first-line option, helped by both anticoagulant and anti-inflammatory effects, with oral alternatives reserved for selected cases.
  • Testing you can skip: Thrombophilia workups are no longer indicated in acute thrombosis, and baseline labs are often unnecessary before starting short-course anticoagulation in otherwise healthy young adults. We cover the exceptions in the chapter.

Iron Deficiency and Iron Infusion

  • Treat before labs return: Symptomatic iron deficiency can be treated before results come back when the story fits, especially in menstruating patients where iron deficiency is common and delay adds little value.
  • Oral iron basics: Ferrous sulfate 324 mg daily is a standard starting option, and absorption improves with meat protein or 500 mg vitamin C while tea and coffee reduce uptake.
  • Expected early response: Symptoms often begin improving within about a week, and hemoglobin should rise by roughly 1 g/dL after two weeks if replacement is working and the diagnosis is right.
  • When IV iron helps: IV iron is the move for oral intolerance, inflammatory bowel disease, marked symptoms, or severe anemia, and one total-dose infusion can often replace a long oral course.
  • Infusion reaction reality: True IV iron allergy is rare; most reactions are complement-mediated infusion effects, and diphenhydramine is the antihistamine to avoid because it can worsen the event. We walk through the bedside response in the episode.

Subscribe to ERcast: Clinical Perspectives to listen to the episode.

References:

  1. Franco L, et al. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost. 2017 Jun;15(6):1142-1154. Epub 2017 Apr 18. PMID: 28316124.
  2. Gandara E, et al. Outcomes of saddle pulmonary embolism: a nested case-control study. J Thromb Haemost. 2011 Apr;9(4):867-9. PMID: 21232009.
  3. Graif A, et al. Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism. J Vasc Interv Radiol. 2020 Apr;31(4):537-543. Epub 2020 Jan 17. PMID: 31959518.
  4. Ho KM, et al. A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. N Engl J Med. 2019 Jul 25;381(4):328-337.  Epub 2019 Jul 7. PMID: 31259488.
  5. Kelkar AH, Rajasekhar A. Inferior vena cava filters: a framework for evidence-based use. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):619-628. PMID: 33275716.
  6. Khan F, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019 Jul 24;366:l4363. PMID: 31340984.
  7. Ortel TL, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 Oct 13;4(19):4693-4738. PMID: 33007077.
  8. Prucnal CK, et al. Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin. Acad Emerg Med. 2020 Feb;27(2):117-127. Epub 2019 Nov 24. PMID: 31625654.
  9. Stevens SM, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016 Jan;41(1):154-64. PMID: 26780744.
  10. Stevens SM, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021 Dec;160(6):e545-e608. Epub 2021 Aug 2. Erratum in: Chest. 2022 Jul;162(1):269. PMID: 34352278.
  11. DeLoughery E, Bannow BS. Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):467-473. PMID: 36485151.
  12. DeLoughery TG. Hematologic concerns in transgender patients. Clin Adv Hematol Oncol. 2022 Aug;20(8):516-523. PMID: 36125958.
  13. LaVasseur C, et al. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost. 2022 Aug 23;6(6):e12763. PMID: 36032216.
  14. Martinelli I, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016 Mar 17;127(11):1417-25. Epub 2015 Dec 22. PMID: 26696010.
  15. Arastu AH, et al. Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions. JAMA Netw Open. 2022 Mar 1;5(3):e224488. Erratum in: JAMA Netw Open. 2022 Jun 1;5(6):e2221567. PMID: 35353168.
  16. DeLoughery TG. Iron Deficiency Anemia. Med Clin North Am. 2017 Mar;101(2):319-332. Epub 2016 Dec 8. PMID: 28189173.
  17. DeLoughery TG. Safety of Oral and Intravenous Iron. Acta Haematol. 2019;142(1):8-12. Epub 2019 Apr 10. PMID: 30970354.
  18. Lo JO, et al. The role of oral iron in the treatment of adults with iron deficiency. Eur J Haematol. 2023 Feb;110(2):123-130. Epub 2022 Nov 20. PMID: 36336470.

Faculty